Concentra Group Holdings Parent, Inc. (CON) Stock Price & Analysis
Concentra Group Holdings Parent, Inc. (CON) closed at USD 39.97 on Thursday, October 22, 2026, up 2.25% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 39.09; the Oct 22, 2026 session ranged USD 38.96–40 on volume of 1,277,185 shares. Market capitalization is $5.10B, with a 52-week range of USD 18.55–40 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:24 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CON.md
Key facts (CON)
- Last four reported quarters (through Jun 30, 2026): revenue $2.29B, net income $199M (8.7% margin), free cash flow $267M (SEC filings).
- Valuation: P/E 25.6x (avg 14.4x at the last 2 fiscal year-ends), EV/EBITDA 14.3x, net debt $1.40B.
- 1 of 80 tracked superinvestors hold CON (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 1.82 on a 1–5 scale) (11 analysts), mean target USD 42 (range 40–47).
- Total return with dividends: 1Y +96.5% vs S&P 500 +14.9%; 5Y +78.7% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 0.44, revenue estimate $605M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CON)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $1.72B | $1.84B | $1.90B | $2.16B | $2.29B |
| Operating income | $259M | $288M | $305M | $334M | $375M |
| Net income | $167M | $180M | $167M | $166M | $199M |
| EPS (diluted) | $1.60 | $1.73 | $1.46 | $1.30 | — |
| Free cash flow | $228M | $169M | $210M | $197M | $267M |
| Operating margin | 15.0% | 15.6% | 16.0% | 15.4% | 16.4% |
| Net margin | 9.7% | 9.8% | 8.8% | 7.7% | 8.7% |
| Revenue growth | — | +6.6% | +3.4% | +13.9% | — |
| Cash + short-term investments | $37.7M | $31.4M | $183M | $79.9M | — |
| Total debt | — | $3.3M | $1.47B | $1.56B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CON)
P/E 25.6x · P/S 2.2x · EV/EBITDA 14.3x · EV/Sales 2.8x · P/FCF 19.1x · P/B 10.7x · FCF yield 5.25% · Earnings yield 3.90% · Dividend yield (paid, TTM) 0.63% · Net debt $1.40B · EV $6.50B
P/E at fiscal year-ends: Dec 2025 15.2x, Dec 2024 13.6x.
Superinvestors (SEC 13F-HR, Q2 2026) (CON)
1 of 80 tracked investors hold CON. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 0.03% | $19.3M | Added +62.1% |
Analysts (CON)
Consensus Buy (mean 1.82 on a 1–5 scale), 11 analysts; mean target USD 42 (low 40, high 47).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-20 | Stephens & Co. | Initiated | Overweight | $45 |
| 2026-10-16 | Jefferies | Initiated | Buy | $47 |
| 2026-09-10 | JP Morgan | Target raised | Overweight | $34 → $43 |
| 2026-08-11 | Wells Fargo | Target raised | Overweight | $28 → $40 |
| 2026-08-10 | Truist Securities | Target raised | Buy | $37 → $42 |
| 2026-08-10 | RBC Capital | Target raised | Outperform | $36 → $42 |
| 2026-07-14 | Truist Securities | Target raised | Buy | $31 → $37 |
| 2026-07-01 | William Blair | Initiated | Outperform |
Total return (dividends reinvested) (CON)
| 1Y (from 2025-10-23) | 5Y (from 2024-07-22) | |
|---|---|---|
| Total return | +96.5% | +78.7% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +96.9% | +29.4% |
| Volatility (annualized) | 27.7% | 27.4% |
| Max drawdown | -13.3% (Feb 2026→Apr 2026) | -20.0% (Aug 2024→Nov 2025) |
CON analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.44 | $0.42 | +4.5% | $605.4M | 10 |
| Next quarter (ends Dec 2026) | $0.29 | $0.28 | +4.2% | $571.5M | 10 |
| Current fiscal year (ends Dec 2026) | $1.65 | $1.52 | +8.2% | $2.35B | 11 |
| Next fiscal year (ends Dec 2027) | $1.84 | $1.69 | +9.1% | $2.50B | 11 |
CON options: expected move
Options price a move of about ±8.6% (±$3.43) by Nov 20, 2026, which includes earnings on Nov 5, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 38.0% | ±8.6% |
| Dec 18, 2026 | 56 | 36.8% | ±11.6% |
| Jan 15, 2027 | 84 | 35.8% | ±13.7% |
| Mar 19, 2027 | 147 | 33.2% | ±16.6% |
| Jun 17, 2027 | 237 | 36.3% | ±22.8% |
30-day implied volatility 35.1% vs 24.5% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:24 UTC)
| Price | USD 39.97 |
|---|---|
| Change | ▲ 2.25% (up) |
| Previous Close | USD 39.09 |
| Open | USD 39.06 |
| Day Range | USD 38.96 – 40 |
| 52-Week Range | USD 18.55 – 40 |
| Volume | 1,277,185 shares |
| Market Cap | $5.10B |
| Exchange | NYQ |
Technical Analysis (CON)
Nexqual's technical model rates CON "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:24 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 74.45 (overbought) |
| vs SMA50 | Above (USD 35.7) |
| MACD | 1.16 (positive) |
Analyst Ratings (CON)
Wall Street analysts rate CON "Buy" based on 11 analysts, with a mean price target of USD 42 (range USD 40–47), per Nexqual as of October 23, 2026 at 09:24 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 42 |
| High Target | USD 47 |
| Low Target | USD 40 |
| Buy / Hold / Sell | 11 / 0 / 0 |
Earnings (CON)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 0.44 |
| Revenue Estimate | $605.38M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.52 vs est 0.42 ▲ beat |
| 2026-03-31 | USD 0.4 vs est 0.34 ▲ beat |
| 2025-12-31 | USD 0.28 vs est 0.28 ▲ beat |
| 2025-09-30 | USD 0.39 vs est 0.38 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financials & Fundamentals (CON)
| Total Revenue | $2.29B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +10.00% |
| Gross Margin | +29.31% |
| Operating Margin | +19.29% |
| Profit Margin | +8.69% |
| ROE | +47.06% |
| Debt / Equity | 4.23 |
| Current Ratio | 1.38 |
| Total Cash | $158.04M |
| Total Debt | $2.14B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $267.42M (11.7% of revenue) |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financial Health Score (CON)
Nexqual rates Concentra Group Holdings Parent, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:24 UTC.
| Growth | Solid — Revenue +14% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 29%, operating 19% (last 12 months) |
| Balance Sheet | Critical — $158M cash and investments vs $1.56B debt (Jun 2026, SEC) |
| Cash Flow | Solid — FCF $267M (last 4 quarters to Jun 2026, SEC), 12% margin |
| Efficiency | Strong — ROE 47%, ROA 8.2% |
Ownership (CON)
| Insider Ownership | +9.65% |
|---|---|
| Institutional Ownership | +90.91% |
| Shares Outstanding | 127.52M |
| Float | 115.27M |
| Short % of Float | +5.09% |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Leadership (CON)
Concentra Group Holdings Parent, Inc. is led by William Keith Newton, CEO & Director, per Nexqual as of October 23, 2026 at 09:24 UTC.
| CEO & Director | William Keith Newton |
|---|---|
| President & CFO | Matthew T. DiCanio |
| Vice President of Strategy & Investor Relations | Bill Chapman |
| Executive VP and Chief Marketing & Innovation Officer | Thomas A. Devasia |
Major Backers & Investors (CON)
Notable institutional backers of Concentra Group Holdings Parent, Inc. include Price (T.Rowe) Associates Inc, T. Rowe Price, TR PRICE-Price (T.Rowe) Mid-Cap Value Equity Trust, according to Nexqual as of October 23, 2026 at 09:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Price (T.Rowe) Associates Inc | 13.89% |
| T. Rowe Price | 5.79% |
| TR PRICE-Price (T.Rowe) Mid-Cap Value Equity Trust | 3.72% |
| Jennison Associates LLC | 2.55% |
| Invesco | 2.29% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 13.92% |
| Vanguard Group | 9.37% |
| State Street | 3.8% |
| Dimensional Fund Advisors | 2.53% |
| Geode Capital | 2.43% |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LFST | LifeStance Health Group, Inc. | USD 12.56 | ▲ 1.87% |
| OPCH | Option Care Health, Inc. | USD 31.29 | ▼ 0% |
| CHE | Chemed Corp | USD 520.15 | ▲ 1.72% |
| NHC | National HealthCare Corporation | USD 243.07 | ▲ 3.17% |
| PACS | PACS Group, Inc. | USD 47.5 | ▲ 1.58% |
| ACHC | Acadia Healthcare Company, Inc. | USD 31.88 | ▲ 1.43% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:24 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt